Emergent BioSolutions Inc. (EBS)

53.41
0.14 0.26
NYSE : Health Technology
Prev Close 53.27
Open 53.55
Day Low/High 52.22 / 53.59
52 Wk Low/High 39.11 / 73.89
Volume 126.22K
Avg Volume 413.10K
Exchange NYSE
Shares Outstanding 51.60M
Market Cap 2.75B
EPS 1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Emergent BioSolutions Reports Financial Results For Second Quarter And Six Months Ended June 30, 2019

Emergent BioSolutions Reports Financial Results For Second Quarter And Six Months Ended June 30, 2019

Reaffirms full year 2019 financial forecast and operational goals Provides Q3 2019 revenue forecast of $245M-$275M GAITHERSBURG, Md.

Emergent BioSolutions Announces Exercise By BARDA Of The First Contract Option, Valued At $261 Million, To Procure Doses Of AV7909 Anthrax Vaccine Candidate For The Strategic National Stockpile

Emergent BioSolutions Announces Exercise By BARDA Of The First Contract Option, Valued At $261 Million, To Procure Doses Of AV7909 Anthrax Vaccine Candidate For The Strategic National Stockpile

AV7909 next generation vaccine positioned as primary solution for U.S. government's anthrax preparedness and response efforts

Emergent BioSolutions To Release Second Quarter 2019 Financial Results And Conduct A Conference Call On August 1, 2019

Emergent BioSolutions To Release Second Quarter 2019 Financial Results And Conduct A Conference Call On August 1, 2019

GAITHERSBURG, Md., July 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

Emergent BioSolutions Looks Like It Will Get a Shot in the Arm

Emergent BioSolutions Looks Like It Will Get a Shot in the Arm

EBS stock is poised to make a tradable rally in the weeks ahead.

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CARG, CLH, KAMN, LONE, NTWK, SALM, SEIC Downgrades: AHC, CTB, EBS Initiations: LEXEB, SFIX Read on to get TheStreet Quant Ratings' detailed report:

Military Might: Top Defense & Security ETF and Stock Picks for a Dangerous World

Military Might: Top Defense & Security ETF and Stock Picks for a Dangerous World

Seven experts select their best ideas among aerospace and naval contractors, drones, building security, biological threats and cybersecurity.

Emergent BioSolutions Reaches Analyst Target Price

Emergent BioSolutions Reaches Analyst Target Price

In recent trading, shares of Emergent BioSolutions Inc have crossed above the average analyst 12-month target price of $56.50, changing hands for $56.61/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Emergent BioSolutions Reaches Analyst Target Price

Emergent BioSolutions Reaches Analyst Target Price

In recent trading, shares of Emergent BioSolutions Inc have crossed above the average analyst 12-month target price of $45.75, changing hands for $46.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

First Week of February 16th Options Trading For Emergent BioSolutions (EBS)

First Week of February 16th Options Trading For Emergent BioSolutions (EBS)

Investors in Emergent BioSolutions Inc saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EBS options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

EBS Crosses Above Average Analyst Target

EBS Crosses Above Average Analyst Target

In recent trading, shares of Emergent BioSolutions Inc have crossed above the average analyst 12-month target price of $44.25, changing hands for $45.48/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Emergent BioSolutions Awarded Department Of National Defence Contract To Supply Anthrasil To The Canadian Government

Emergent BioSolutions Awarded Department Of National Defence Contract To Supply Anthrasil To The Canadian Government

Health Canada approves Anthrasil® under Extraordinary Use New Drug Regulations

Six Off the Beaten Path Healthcare Stock Gems

Six Off the Beaten Path Healthcare Stock Gems

These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.

TheStreet Quant Rating: C (Hold)